Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

UnitedHealth Group Inc.

UNH

NEUTRAL

May 22, 2026

Research Conclusion

UnitedHealth Group at ~$391/share is HOLD / RECOVERY BET — not a standard compounder thesis. The PWFV of ~$430/share implies only +10% upside at current levels, but with materially negative skew: the bear case (-44%) and severe case (-72%) are more damaging than the bull case (+69%) is beneficial. The stock is cheap on normalized earnings (FY2028E $32 at ~12x) but the path to normalization requires two simultaneous positive resolutions — DOJ investigation settling benignly AND Medical Loss Ratio normalizing — neither of which is certain. The unprecedented coordinated insider buying ($31.6M at $288-291 in May 2025) by the CEO, CFO, and three directors is the single most constructive signal.

Company Overview & Moat Assessment

UnitedHealth Group is the largest US health insurer and managed care company by revenue ($447.6B in FY2025), serving approximately 50 million members across commercial, Medicare Advantage, Medicaid, and international markets through its UnitedHealthcare segment. Its Optum segment is a high-margin services engine comprising OptumHealth (90,000+ affiliated physicians in value-based care), OptumRx (top-tier PBM), and OptumInsight (healthcare data analytics and revenue cycle management). The company is in a documented earnings trough — FY2025 net income of $12.1B ($13.23 EPS) versus $22.4B ($23.86 EPS) in FY2023 — driven by elevated Medical Loss Ratio, a DOJ criminal investigation into Medicare Advantage billing practices, and the aftermath of the Change Healthcare cyberattack. The normalized earnings power is $30-45B in operating income once the trough passes.

▲ Bull Case

  • ◆DOJ resolves as civil settlement <$2B with minimal operational conditions — removes the 1-2pp risk premium, triggers relief rally. Combined with CMS 2026 rate tailwind, FY2026 earnings beat consensus materially. Multiple re-rates from ~9.5% WACC to ~8.0% WACC → fair value $550-660/share.
  • ◆MLR normalizes to 83-84% by FY2027 as CMS rate increases compound and Hemsley drives medical cost discipline. EPS $30+ at 22x P/E = $660/share. Optum grows 12%/yr organically with cyber and open-banking healthcare data optionality.
  • ◆GLP-1 mandates are avoided or offset — CMS does not mandate obesity GLP-1 coverage for MA plans; drug manufacturer rebates cushion diabetes GLP-1 costs; Optum's PBM rebate scale creates offsetting benefit.

▼ Bear Case

  • ◆DOJ consent decree impairs MA billing economics — settlement requires HCC risk adjustment coding changes that reduce per-member capitation revenue by $2-4B/yr permanently. Operating margin recovers to 5-6% (not 8%+). EPS peaks at $18-20. Stock: $250-280.
  • ◆GLP-1 wave hits before premium rates catch up — CMS mandates obesity GLP-1 coverage, adding 200-400bps to MLR in a single year. MLR stays at 86-88% instead of normalizing to 84%. Earnings recovery invalidated for 2-3 additional years. EPS FY2027E: ~$14-16 at 12-14x = $168-224/share.
  • ◆Q1 2026 revenue deceleration (+1.9%) accelerates — if Q2-Q3 also show low single-digit growth, it signals MA membership contraction or Optum slowdown. Revenue stagnating at $450-460B creates L-shaped recovery, not V-shaped.
Primary Debate on Wall Street

“The core question: Is FY2025 an unprecedented cyclical trough from which UNH fully recovers (bull, ~60% of analysts) or a permanent reset from regulatory action + structural costs that prevents normalization (bear, ~40%)? Bull view: MLR elevation is cyclical—it has happened before and normalized. CMS rates always eventually catch up. Optum is irreplaceable. At 12-15x normalized earnings, the stock is deep value. Bear view: The DOJ investigation is existential with no precedent at this scale. GLP-1 wave is structural, not cyclical. Vertical integration faces permanent antitrust headwinds. The market correctly applies a 30-40% discount to normalized value. This analysis concludes both views are partially right — the probability-weighted +10% PWFV suggests fair valuation at $391 with DOJ premium already priced in.”

Top Catalysts
  • ◆DOJ settlement announcement (timing 12-36 months; +30-40% on civil settlement <$2B; -40-60% on criminal charges) — the single highest-magnitude catalyst
  • ◆Q2-Q3 2026 MLR data (August 2026 earnings) — if MLR trends toward 85% from 86-88%, recovery thesis confirmed; +10-20% re-rating
  • ◆CMS 2027 MA rate announcement (February 2027) — continued rate tailwind sustains MLR normalization momentum
  • ◆FY2026 EPS guidance reinstatement — UNH withdrew guidance; reinstating signals management confidence; +5-10% re-rating
  • ◆GLP-1 CMS ruling — positive (no obesity mandate) +5-10%; negative (mandated coverage) -10-20%
Top Risks
  • ◆DOJ criminal conviction (5-15% probability, catastrophic impact) — Medicare/Medicaid debarment = -60 to -80% stock move; single highest-severity risk
  • ◆GLP-1 mandatory MA coverage (HIGH probability; HIGH structural impact) — 200-400bps MLR increase caps recovery at 85-87%; -30-40%
  • ◆MLR persistence (MEDIUM probability; HIGH impact) — if MLR doesn't normalize by FY2027, earnings recovery thesis fails; -40-50%
  • ◆Antitrust forced divestiture (MEDIUM probability; HIGH impact) — FTC or DOJ forces Optum or OptumRx divestiture; removes primary value engine
  • ◆MA Stars rating decline — quality bonuses are meaningful revenue component; downgrade reduces per-member revenue and compounds MLR problem

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/UNH/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.